

ABUHB High Cost Drugs Group

Monday 26th September 2022

14:00 on Microsoft Teams

Meeting Notes

Item	Published	60 day imp deadline	Implementation Plan reviews	Actions
	17/8/22	16/10/22	NICE ID3848: Upadacitinib for treating ankylosing spondylitis Rheum, SC	Group approved- add to formulary
	28/7/22	26/9/22	NICE ID3902: Brolucizumab for treating diabetic macular oedema Ophth, SC	Group approved- add to formulary
	29/6/22	28/8/22	NICE ID3960: Upadacitinib, abrocitinib and tralokinumab for dermatitis Derm, SC Predicted numbers 20 (at odds with NICE estimate of 400) NICE guidance collates all drugs together under one guidance. Derm have not been able to identify how many pts will be allocated to each therapy. Approx 400 pts- some of these will be managed conservatively/standard therapy and some will require specialist sec care meds. Little data available about which proportion of these will require these systemic therapies. Unknown what the capacity of our department is like to see these pts also.	Group approved pending BPA approval
Item	Published	60 day imp deadline	Implementation Plans not yet received	
	18/5/22	17/7/22	NICE ID3898: Faricimab for treating age-related macular degeneration Ophth, SC	Lack of ophthalmology engagement discussed. Reiterated process of getting HCD on formulary- these remain off formulary until ophth engage with process. JVG doing work on pathways.
	18/5/22	17/7/22	NICE ID3899: Faricimab for treating diabetic macular oedema Ophth, SC	
	11/8/22	10/10/22	NICE ID3951: Dexamethasone intravitreal implant for treating DMO in people without a psuedophakic lens	EK to continue to chase
Also not received- signed implementation plan for Icosapent Ethyl below. [REDACTED] has completed this plan and HCDIPG approved it pending BPA signature but no BPA will put their signature on it due to ongoing discussions around where the budget for this should sit.				
	10/6/22	9/8/22	NICE ID3831 Icosapent Ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	CC to progress with finance colleagues.

Date of next meeting: 24th October 2022